Shares of Translate Bio Inc (NASDAQ:TBIO) saw strong trading volume on Friday . 363,602 shares traded hands during trading, an increase of 87% from the previous session’s volume of 193,995 shares.The stock last traded at $8.30 and had previously closed at $7.88.
Several equities analysts recently weighed in on the stock. HC Wainwright assumed coverage on shares of Translate Bio in a research report on Monday, December 24th. They set a “buy” rating and a $21.00 price target for the company. ValuEngine lowered shares of Translate Bio from a “buy” rating to a “hold” rating in a research report on Friday, December 21st. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $22.75.
The company has a debt-to-equity ratio of 0.91, a quick ratio of 16.71 and a current ratio of 16.72.
A number of large investors have recently modified their holdings of the business. FMR LLC boosted its position in Translate Bio by 6.8% during the fourth quarter. FMR LLC now owns 6,771,313 shares of the company’s stock worth $50,785,000 after purchasing an additional 433,952 shares during the period. Baupost Group LLC MA boosted its position in Translate Bio by 237.5% during the third quarter. Baupost Group LLC MA now owns 6,491,287 shares of the company’s stock worth $62,393,000 after purchasing an additional 4,568,211 shares during the period. Atlas Venture Advisors Inc. bought a new position in Translate Bio during the fourth quarter worth about $29,415,000. BlackRock Inc. boosted its position in Translate Bio by 130.2% during the fourth quarter. BlackRock Inc. now owns 982,405 shares of the company’s stock worth $7,367,000 after purchasing an additional 555,635 shares during the period. Finally, Federated Investors Inc. PA boosted its position in Translate Bio by 12.6% during the third quarter. Federated Investors Inc. PA now owns 800,000 shares of the company’s stock worth $8,000,000 after purchasing an additional 89,805 shares during the period. Hedge funds and other institutional investors own 59.36% of the company’s stock.
Translate Bio Company Profile (NASDAQ:TBIO)
Translate Bio, Inc, a messenger RNA therapeutics company, engages in developing medicines to treat diseases caused by protein or gene dysfunction. It is developing MRT5005 that is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 for the treatment of ornithine transcarbamylase deficiency.
Recommended Story: Bollinger Bands
Receive News & Ratings for Translate Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Translate Bio and related companies with MarketBeat.com's FREE daily email newsletter.